Establishment of human post-vaccination SARS-CoV-2 standard reference sera
Jinhua Xiang; Louis Katz; Patricia L. Winokur; Ashok Chaudhary; Rebecca Bradford; Sujatha Rashid; Sudakshina Ghosh; Angela Robertson; Joseph Menetski; Taylor Lee; Brittany Poelaert; Richard T. Eastman; Matthew D. Hall; Jack T. Stapleton.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22269773
As SARS-CoV-2 variants emerge, there is a critical need to understand the effectiveness of serum elicited by different SARS-CoV-2 vaccines. A reference reagent comprised of post-vaccination sera from recipients of different vaccines allows evaluation of in vitro variant neutralization, and provides a reference for comparing assay results across laboratories. We prepared and pooled >1 L serum from donors who received the SARS-CoV-2 mRNA vaccines (BNT162b2, Pfizer and mRNA-1273, Moderna), a replication-incompetent adenovirus type 26 vaccine (Ad26.COV2.S, Johnson and Johnson), or recombinant spike protein expressed by baculovirus incorporated into a nanoparticle vaccine plus Matrix-M adjuvant (NVX-CoV2373, Novavax). Twice frozen sera were aliquoted and are available for distribution to the research community (BEI Resources). The calculated WHO titer of pooled sera to spike protein was 1,312, 1,447, 1,936, and 587 and the reciprocal RBD binding to ACE-2 IC90-titers were 60, 64, 118, and 46 for BNT162b2, mRNA1273, Ad26.CoV2373, and NVX-CoV2373 sera, respectively.
Texto completo
Documentos relacionados